![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 36, 25386-25392, September 3, 1999
,
,
,
,
,
,
, and
**
From the
Department of Metabolic Diseases and
Department of Physiology, Graduate School of Medicine,
University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan,
§ Department of Physiology, Hirosaki University School of
Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan, and ¶ Department
of Morphogenesis, Institute of Molecular Embryology and Genetics,
Kumamoto University School of Medicine, 4-24-1 Kuhonji, Kumamoto 862, Japan
| |
ABSTRACT |
|---|
|
|
|---|
The NADH shuttle system is composed of the glycerol phosphate and malate-aspartate shuttles. We generated mice that lack mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH), a rate-limiting enzyme of the glycerol phosphate shuttle. Application of aminooxyacetate, an inhibitor of the malate-aspartate shuttle, to mGPDH-deficient islets demonstrated that the NADH shuttle system was essential for coupling glycolysis with activation of mitochondrial ATP generation to trigger glucose-induced insulin secretion.
The present study revealed that blocking the NADH shuttle system
severely suppressed closure of the ATP-sensitive potassium (KATP) channel and depolarization of the plasma
membrane in response to glucose in In pancreatic It has been known that pyruvate, an end product of aerobic glycolysis,
cannot stimulate insulin secretion although it is oxidized as
efficiently as glucose in However, the mechanism by which deprivation of cellular ATP led to the
downstream events that culminated in abrogation of insulin secretion
was not addressed in the previous study. Under the conditions where the
NADH shuttle system was stopped, the change in
[Ca2+]c in response to glucose was significantly
impaired. An initial drop below a base line and the first phase peak of [Ca2+]c failed to occur, although it was followed
by a gradual elevation of [Ca2+]c to the second
phase plateau level in 10 to 15 min (20). These results suggested that
Ca2+ uptake of endoplasmic reticulum by
Ca2+-ATPase and Ca2+ influx through VDCCs from
the extracellular compartment were severely impaired (24-26). In Islet Isolation and Analysis of Insulin Secretion--
Insulin secretion from islets
was measured with Krebs-Ringer bicarbonate buffer with a basal glucose
concentration of 2.8 mM unless otherwise stated. Batch
incubation was performed with 10 islets/tube at 37 °C for 1 h
after preincubation with the basal glucose concentration for 20 min.
Perifusion experiments were performed with 30 islets/chamber at
37 °C with a flow rate of 0.6 ml. AOA, when used, was added to both
preincubation and incubation medium. AOA and diazoxide were purchased
from Sigma.
Measurement of [Ca2+]c--
A single islet
was placed under a microscope (IMT-2, Olympus, Japan) and perifused
with Sol II buffer containing 150 mM NaCl, 5 mM
KCl, 1.0 mM MgCl2, 2.0 mM
CaCl2, and 10 mM HEPES (pH 7.4) at 37 °C.
Fluorescence was excited with light emitted from a xenon lamp (TILL
Photonics, Germany), collected through interference filters (Olympus,
Japan), and detected using a photomultiplier (NT5783, Hamamatsu
Photonics, Japan). Islets were loaded with 15 µM
fura-2/acetoxymethylester (Molecular Probes, Eugene, OR) at 37 °C
for 1 h. The fluorescence was excited with a dual-wavelength ratiometric mode at 340 and 380 nm. The emission wavelength was filtered at 500 nm.
Electrical Recordings--
Dispersed islet cells were kept in a
35-mm Petri dish on an inverted microscope. Identification of Measurement of Islet ATP Content--
Ten islets were incubated
with Krebs-Ringer bicarbonate buffer containing 2.8, 10.0, or 16.7 mM glucose at 37 °C for 1 h. After aspiration of
medium, the metabolism was snap-stopped by an addition of ice-cold 1 N perchloric acid and freezing with liquid nitrogen. Then,
samples were thawed, sonicated, and neutralized with NaOH (40). ATP
content was measured using a luciferase-luciferin system (Sigma).
Statistical Analysis--
Data were expressed as means ± S.E. Statistical significance was evaluated with the Student's
t test or by analysis of variance.
Effect of AOA on Glucose-responsive Changes in Insulin Secretion
and [Ca2+]c in mGPDH-deficient Islets--
In
static incubation for 1 h, the increase in insulin secretion
stimulated by 16.7 mM glucose was inhibited by 94% in
mGPDH-deficient mice islets treated with 5 mM AOA
(0.11 ± 0.03 ng/islet/h) compared with wild-type islets without
AOA (1.83 ± 0.19 ng/islet/h). Perifusion experiments revealed
that the first phase of the secretion was severely decreased and the
second phase was totally abrogated (Fig.
1A, closed squares)
compared with wild-type islets without AOA (Fig. 1A, closed
circles). The inhibitory effect of AOA on glucose-induced insulin
secretion from mGPDH-deficient islets was dose-dependent,
and the half-maximal inhibitory concentration of AOA was ~1
mM at 16.7 mM glucose (Fig. 1B). As
previously reported (20), an initial small drop and the first phase
peak of [Ca2+]c, which were normally observed in
wild-type islets without AOA in response to 22.2 mM glucose
(Fig. 1C, left panel), disappeared when 5 mM AOA was applied to mGPDH-deficient islets (Fig.
1C, right panel). However,
[Ca2+]c gradually rose in 10 to 15 min to the
second phase plateau level, which was comparable to that of wild-type
islets without AOA. At 1 mM AOA, the initial drop and the
subsequent first phase peak of [Ca2+]c remained
missing, whereas the second phase plateau was reached in 6 to 8 min
(data not shown). These results suggested that both the appearance of
the first phase peak of [Ca2+]c and the time
required to raise [Ca2+]c to the second phase
level were dependent on glucose metabolism through the NADH shuttle
system and that loss of function of the shuttle system impaired
Ca2+ influx into the cytosol. Stimulation by 15 mM glucose instead of 16.7 or 22.2 mM glucose
produced essentially similar results to the above experiments.
Effect of AOA on the Membrane Potential in mGPDH-deficient
Application of 0.5 mM tolbutamide to extracellular solution
caused the depolarization of the plasma membrane and generated action
potentials even in mGPDH-deficient
Because the second phase plateau of [Ca2+]c was
attained within 10 to 15 min after glucose stimulation in
mGPDH-deficient islets treated with 5 mM AOA (Fig.
1C, right panel), we presumed that the membrane
potential of Effect of AOA on the KATP Channel Current in
mGPDH-deficient Electrophysiological Characteristics of the KATP
Channel on the Excised Plasma Membrane--
We then performed
electrophysiological analyses of the KATP channel itself in
an inside-out patch of the plasma membrane excised from Inhibition by ATP of the KATP Channel Current on the
Excised Plasma Membrane--
We next studied the effect of ATP on the
KATP channel activity in the inside-out mode with the
recording voltage at Role of the NADH Shuttle System in Steps Distal to an Elevation of
[Ca2+]c--
When both the NADH shuttles were
stopped by treating mGPDH-deficient
To evaluate glucose metabolism leading to ATP generation in islets, we
measured the ATP content of islets after glucose stimulation for 1 h in the presence of 250 µM diazoxide and 30 mM KCl. At 2.8 mM glucose, the ATP content of
mGPDH-deficient islets treated with 5 mM AOA was 10.5 ± 0.3 pmol/islet, which was not different from that of wild-type
islets (10.1 ± 0.7 pmol/islet). However, the ATP contents of
mGPDH-deficient islets treated with AOA were significantly less than
those of wild-type islets at both 10.0 mM glucose
(11.2 ± 0.2 versus 13.1 ± 0.6 pmol/islet,
respectively, p < 0.01) and 16.7 mM
glucose (12.0 ± 0.4 versus 15.4 ± 0.05 pmol/islet, respectively, p < 0.01) (Fig.
7). These results indicated that efficient ATP generation by glucose metabolism through the NADH shuttles was important in the steps distal to elevation of
[Ca2+]c in glucose-induced insulin secretion. The
ATP contents in wild-type islets incubated with diazoxide and KCl were
comparable to those in wild-type islets incubated without diazoxide or
KCl at 2.8, 10.0, and 16.7 mM glucose (data not shown).
This study is the first to provide direct evidence that the NADH
shuttle system plays an essential role in regulating both the
KATP channel-dependent pathway and steps distal
to Ca2+ influx through the plasma membrane in
glucose-induced insulin secretion. The KATP channels are a
weak inward rectifier that are expressed in a wide variety of tissues
including pancreatic The mGPDH-deficient There was an evident dissociation between the elevation of
[Ca2+]c (Fig. 1C, right
panel) and the inhibition of insulin secretion (Fig.
1A, closed squares) when the NADH shuttle system was blocked in islets. First, it should be considered that steps distal
to an elevation of [Ca2+]c such as mobilization
of secretory granules toward the plasma membrane, energization of the
granules, and a final fusion process have been shown to be
ATP-requiring (30). Consistent with this notion, when inhibitors of
oxidative phosphorylation were applied to An apparent difference was also observed in Ca2+ behavior
in response to glucose between an islet and a single Diazoxide, which directly and selectively opens the KATP
channel without interfering with In conclusion, we have clarified the two mechanisms by which the
shutdown of the NADH shuttle function abolished glucose-induced insulin
secretion. The insufficient closure of the KATP channel due
to the depletion of cellular ATP was followed by impairment of the
depolarization of the plasma membrane and Ca2+ influx into
cells, although properties of
the KATP channel on the excised
cell membrane were
unaffected. In mGPDH-deficient islets treated with aminooxyacetate,
Ca2+ influx through the plasma membrane induced by a
depolarizing concentration of KCl in the presence of the
KATP channel opener diazoxide restored insulin secretion.
However, the level of the secretion was only ~40% of wild-type
controls. Thus, glucose metabolism through the NADH shuttle system
leading to efficient ATP generation is pivotal to activation of both
the KATP channel-dependent pathway and steps
distal to an elevation of cytosolic Ca2+ concentration in
glucose-induced insulin secretion.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
cells, glucose metabolism in glycolysis and in
mitochondria is pivotal to glucose-induced insulin secretion. Thus,
mutations in the glucokinase gene (1, 2) and mitochondrial DNA (3) can
cause type 2 diabetes mellitus, which is characterized by insufficient
insulin secretion in response to glucose. Moreover, abrogation of
cell-specific glucokinase in mice (4, 5) and mitochondrial DNA in
insulinoma cell lines (6-9) was associated with defective insulin
secretion in response to glucose. The following cascade has been
generally accepted as the glucose-induced insulin secretory pathway
(10-13). Glucose-stimulated increase in cytosolic ATP or in the ratio
of ATP to ADP closes ATP-sensitive potassium (KATP)1 channels,
which depolarizes the plasma membrane potential above a threshold,
leading to Ca2+ entry into the cytosol through activation
of voltage-dependent Ca2+ channels (VDCCs). The
rise in cytosolic Ca2+ concentration
([Ca2+]c) is thought to finally trigger
exocytosis of insulin from secretory vesicles.
cells (14, 15). Studies with an inhibitor
of pyruvate transport into mitochondria or an inhibitor of the
tricarboxylic acid cycle suggested that metabolism of glucose-derived pyruvate in mitochondria or in the tricarboxylic acid cycle was not
well correlated with glucose-induced insulin secretion (16, 17). These
results suggested that glycolysis-derived factor(s) other than pyruvate
are required for activation of mitochondrial metabolism and for
generation of the metabolic signals such as ATP. NADH, which is
generated at a step catalyzed by a glycolytic enzyme glyceraldehyde-3
phosphate dehydrogenase, is one such candidate. This is because the
electrons of the cytosolic NADH are transferred into the mitochondrial
electron transfer chain directly through the NADH shuttle system and
enhance the mitochondrial membrane potential. There are two known NADH
shuttles, the glycerol phosphate shuttle and malate-aspartate shuttle
(18, 19). Recently, we have generated mice that lack mitochondrial
glycerol-3-phosphate dehydrogenase (mGPDH), a rate-limiting enzyme of
the glycerol phosphate shuttle (20). When aminooxyacetate (AOA), a well
characterized inhibitor of aspartate aminotransferases in the
malate-aspartate shuttle (19, 21-23), was applied to mGPDH-deficient
islets, glucose-induced increases in glucose oxidation at the
tricarboxylic acid cycle, production of NAD(P)H autofluorescence,
hyperpolarization of mitochondrial membrane potential, calcium influx
into mitochondria, and cellular ATP content were severely impaired, and
insulin secretion was completely abrogated (20). These results
demonstrated that the NADH shuttle system is essential for coupling
glycolysis with mitochondrial ATP generation to trigger glucose-induced
insulin secretion.
cells, the activity of VDCCs is controlled by the plasma membrane
potential, which in turn is mainly regulated by the activity of the
KATP channel (27-29). Thus, we hypothesized that glucose
metabolism without the functional NADH shuttle system was not
sufficient to close the KATP channel due to inefficient
generation of ATP and to elicit depolarization of the plasma membrane
and generation of action potentials. Moreover, steps distal to an
elevation of [Ca2+]c are also energy-requiring
(30-33). These steps including mobilization of secretory granules
toward the plasma membrane, priming of the granules, and a final fusion
process may also have been affected. In this article, using
electrophysiological techniques we provide evidence that glucose
metabolism through the NADH shuttle system is essential to regulate the
KATP channel-dependent pathway in
glucose-induced insulin secretion. In addition, with diazoxide and a
depolarizing concentration of KCl we show that steps distal to an
elevation of [Ca2+]c are also regulated by
glucose metabolism through the system.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Cell Preparation--
Isolation of
islets from mGPDH-deficient mice (20) and their wild-type littermates
was carried out as described previously (34). In brief, after clamping
the common bile duct at a point close to the duodenum outlet, 2.5 ml of
Krebs-Ringer bicarbonate buffer (118.4 mM NaCl, 4.7 mM KCl, 1.3 mM MgSO4, 1.2 mM KH2PO4, 2.0 mM
CaCl2, 10 mM NaHCO3, and 10 mM HEPES at pH 7.4) containing collagenase (Sigma) was
injected into the duct. The swollen pancreas was taken out and
incubated at 37 °C for 3 min. The pancreas was dispersed by
pipetting and washed two times with Krebs-Ringer bicarbonate buffer.
Islets were collected by manual picking and incubated in RPMI medium
(Life Technologies, Inc.) supplemented with 100 units/ml penicillin,
100 µg/ml streptomycin, and 10% fetal calf serum. Isolation of
single
cells was performed using 1000 units/ml dispase (Godo
Shusei, Japan), as described previously (35).
cells
from other islet cells was carried out by detecting the excitatory
electrical response of the cells to 15 mM glucose or to 0.5 mM tolbutamide. The patch clamp method was used to record
membrane currents and membrane potential with an EPC-7 patch-clamp
amplifier (List Electronic, Germany) (36, 37). The resistance of
electrodes made of borosillicate glass capillaries was 2-4 megaohms.
For recording the plasma membrane potential, the nystatin-perforated
whole-cell configuration was used (38, 39). For recording the
whole-cell membrane currents, the conventional whole-cell mode was
used. The membrane capacitance ranged from 12 to 20 picofarads. The
membrane potential was repeatedly changed from
90 to
50 mV by ramp
pulses with a ramp pulse generator (SET-2100, Nihon Kohden, Japan).
Both the rising and falling time of each ramp pulse was 2 s in
duration. In the inside-out mode, single channel currents were
recorded. The data were analyzed by using a single channel current
analysis program (QP-129J, Nihon Kohden). All experiments were
performed at room temperature. The standard extracellular solution
contained 130 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 1 mM CaCl2, 2 mM glucose, and 10 mM HEPES (pH 7.3). When the
cells were stimulated with glucose, sucrose was added to the control
solution to adjust the osmolarity. In the nystatin-perforation recordings, the pipette solution contained 135 mM KCl, 1.2 mM MgCl2, 0.5 mM EGTA, 200 µg/ml
nystatin (Sigma), and 10 mM HEPES (pH 7.3). In the
conventional whole-cell recordings, the pipette solution contained 100 mM potassium gluconate, 35 mM KCl, 1.2 mM MgCl2, 0.5 mM EGTA, 1 mM Na2ATP, 1 mM GTP, 2 mM glucose, and 10 mM HEPES (pH 7.2). In single
channel recordings, both pipette (external) and internal solutions
contained 135 mM KCl, 1.2 mM MgCl2,
0.5 mM EGTA, 5 mM tetraethylammonium chloride
(Sigma), 10 mM glucose, and 10 mM HEPES. The pH
was 7.3 in the external solution and 7.2 in the internal solution.
Cells in the bath were superfused with a stream of an extracellular
solution. Drugs were dissolved in the extracellular solution and
applied to cells by switching flow tubes.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (24K):
[in a new window]
Fig. 1.
Effects of AOA on glucose-induced insulin
secretion and change in [Ca2+]c in
mGPDH-deficient islets. A, glucose-induced insulin
secretion from wild-type islets (closed circles,
n = 4) and from mGPDH-deficient islets treated with 5 mM AOA (closed squares, n = 4).
Glucose (G) concentration was raised from 2.8 to 16.7 mM at 0 min in perifusion experiments. B,
dose-dependent inhibition by AOA of 16.7 mM
glucose-induced insulin secretion from mGPDH-deficient islets. The
islets were incubated in the presence of 0, 0.5, 0.75, 1.0, 2.0, 3.0, or 5.0 mM AOA for 1 h (n = 4).
C, glucose-induced changes in [Ca2+]c.
Wild-type (WT) islets (left panel) or
mGPDH-deficient islets treated with 5 mM AOA (right
panel) were challenged by 22.2 mM glucose, and changes
in [Ca2+]c were monitored with fura-2
fluorescence. Representative traces shown are from at least four
experiments.
Cells--
We next directly measured the plasma membrane potential of
cells with patch clamp techniques. Under the nystatin-perforated whole-cell mode, the resting membrane potentials in the presence of 2 mM glucose were
58.4 ± 1.3 mV (n = 24) in wild-type
cells,
61.5 ± 1.6 mV (n = 24) in wild-type
cells with 5 mM AOA,
61.3 ± 1.9 mV (n = 23) in mGPDH-deficient
cells, and
62.5 ± 1.7 mV (n = 22) in mGPDH-deficient
cells with 5 mM AOA. There were no significant differences
among the four groups. In wild-type
cells treated with 5 mM AOA, stimulation by 15 mM glucose normally depolarized the plasma membrane potential to ~50 mV in 70-90 s, where action potentials were generated (Fig.
2A). These normal responses
were also observed in mGPDH-deficient
cells without AOA (Fig.
2B). However, in mGPDH-deficient
cells treated with 5 mM AOA, the membrane potential was only minimally
depolarized in response to 15 mM glucose and failed to
reach the threshold and to generate action potentials within the
measurement period of 4 min (Fig. 2C).

View larger version (24K):
[in a new window]
Fig. 2.
Measurement of the plasma membrane potential
of
cells in a nystatin-perforated whole-cell
mode. Glucose concentration was raised from 2 to 15 mM
at indicated points. A, wild-type (WT)
cell
treated with 5 mM AOA. B, mGPDH-deficient
cell. C, mGPDH-deficient
cell treated with 5 mM AOA. D, mGPDH-deficient
cells treated
with 5 mM AOA. Tolbutamide (0.5 mM) was applied
to the cell as indicated after glucose stimulation. E, the
plasma membrane potential was monitored for 15 min after 15 mM glucose stimulation in mGPDH-deficient
cell treated
with 5 mM AOA. The electrical activity was observed 6 min
after glucose stimulation in this trace. Representative traces shown
are from at least six experiments.
cells treated with AOA (Fig.
2D). This suggested that sensitivity of the KATP
channel to sulfonylurea was preserved under these conditions.
cells might take longer to reach the threshold. The
measurement period was then extended to 15 min. Under these conditions,
membrane depolarization and generation of action potentials were
observed in 2 of 6 experiments; one at 6 min (Fig. 2E), and
the other at 7 min after the glucose stimulation. Thus, small number of
mGPDH-deficient
cells treated with AOA retained electrical
excitability to glucose stimulation, although the initiation of the
response was markedly delayed.
Cells--
We then studied the KATP
channel current in response to glucose in a conventional whole-cell
mode. Ramp voltage pulses from
90 mV to
50 mV were given every
4 s. In mGPDH-deficient
cells, the KATP channel
current in response to the 40-mV voltage pulse was decreased from ~40
to ~15 pA by elevation of the extracellular glucose concentration
from 2 to 15 mM (Fig.
3A, upper panel). At several time points during the trace, the mode of recording was
transiently changed to a current clamp mode, where a stepwise depolarization of the membrane potential culminating in the generation of action potentials was clearly observed (Fig. 3A,
lower panel). However, in mGPDH-deficient
cells treated
with 5 mM AOA, no decrease in the KATP channel
current (Fig. 3B, upper panel) or depolarization
of the membrane potential (Fig. 3B, lower panel) in response to 15 mM glucose was observed. In contrast,
application of 0.5 mM tolbutamide to the cells reversibly
abolished the KATP channel current (Fig. 3B,
lower panel).

View larger version (48K):
[in a new window]
Fig. 3.
Measurement of the KATP channel
current in
cells in a conventional whole-cell
mode. The KATP channel current (I) and
applied voltage (V) were shown. Glucose concentration was
raised from 2 to 15 mM at indicated points. The clamp mode
was transiently changed to a current clamp mode to monitor the plasma
membrane potential. A, wild-type (WT)
cell.
B, mGPDH-deficient
cells treated with 5 mM
AOA. Tolbutamide (0.5 mM) was applied to the cell as
indicated. Representative traces shown are from at least four
experiments.
cells. At a
recording voltage of
60 mV, the amplitude of the KATP
channel current in mGPDH-deficient
cells was the same as in
wild-type
cells (Fig. 4A).
When the KATP channel currents were plotted against the
recording voltage from
60 mV to 60 mV at an interval of 10 mV, the
current-voltage relationship of mGPDH-deficient
cells essentially
overlapped that of wild-type
cells, which show a weak inward
rectification (Fig. 4B). The single KATP channel
conductance of mGPDH-deficient
cells measured between
60 mV and 0 mV was 73.1 ± 3.8 picosiemens (n = 4) and was not
different from that of wild-type
cells (72.7 ± 3.3 picosiemens, n = 4).

View larger version (21K):
[in a new window]
Fig. 4.
Measurement of electrophysiological
characteristics of the KATP channel on the
cell membrane in an inside-out patch clamp
mode. A, the KATP channel currents were
recorded at
60 mV on the excised
cell membrane from wild-type
(WT) islets (upper panel) and from
mGPDH-deficient islets (lower panel). B, the
current-voltage relationships of the KATP channel on the
excised
cell membrane from wild-type islets (open
circles, n = 4) and from mGPDH-deficient islets
(open squares, n = 4) are shown.
60 mV. When 1 mM ATP was applied to
the cytoplasmic surface of mGPDH-deficient
cell plasma membranes,
the KATP channel current was immediately and completely
abolished (Fig. 5A). The
channel open probabilities at 0.1, 1, 10, 100, and 1000 µM ATP in mGPDH-deficient
cells were not different
from those in wild-type
cells (Fig. 5B). These values
were well in accordance with the theoretical values calculated with the
Hill equation (41) (Fig. 5B). Thus, the electrophysiological
characteristics of the KATP channel and its sensitivity to
ATP per se were normal in mGPDH-deficient
cells.

View larger version (20K):
[in a new window]
Fig. 5.
Sensitivity to ATP of the KATP
channel on the
cell membrane.
A, measurement of the KATP channel current on
the excised membrane of mGPDH-deficient
cells. ATP (1 mM) was applied inside the patch membrane as indicated.
B, the relative KATP channel open time. ATP
(0.1, 1, 10, 100, or 1000 µM) was applied to wild-type
cell membrane (open circles, n = 6) and
to mGPDH-deficient
cell membrane (open squares,
n = 6). Theoretical curves for wild-type
cell
(solid line) and mGPDH-deficient
cell (dotted
line) were drawn according to a Hill equation;
(G/G0)=1/(1 + ([ATP]/ki)h), where G is open
time probability with ATP at each concentration,
G0 is open time probability without ATP, [ATP]
is concentration of ATP, ki is ATP concentration at
which the inhibition is half maximal, and h is the Hill
coefficient. For wild-type
cell membrane (n = 6),
G0 = 0.20 ± 0.02, ki = 10.5 ± 1.6 µM, and h = 1.35 ± 0.05. For mGPDH-deficient
cell membrane (n = 6),
G0 = 0.21 ± 0.02, ki = 9.5 ± 0.3 µM, and h = 1.38 ± 0.01.
cells with 5 mM
AOA, the first phase peak of [Ca2+]c in response
to glucose disappeared (Fig. 1C, right panel).
Moreover, it took 10 to 15 min for [Ca2+]c to
reach the second phase plateau. These findings indicated an impairment
of Ca2+ influx through the plasma membrane during this
period. We then postulated that a restoration of Ca2+
influx could recover insulin secretion. To test this, islets were
treated with diazoxide, a KATP channel opener, to hold the KATP channel open in combination with a high concentration
of KCl to depolarize the plasma membrane. Under these conditions, it
has been shown that glucose does not further elevate
[Ca2+]c but amplifies the actions of
Ca2+ on the insulin-secreting processes (31, 32, 42, 43). With application of 30 mM KCl in the presence of 250 µM diazoxide, the insulin secretory response to glucose
was indeed restored in mGPDH-deficient islets treated with 5 mM AOA (Fig. 6,
A-C, closed squares). The amounts of secreted
insulin were increased by elevating glucose concentration from 2.8 to
10.0 mM and to 16.7 mM. Insulin released by
this treatment was, however, still ~60% lower than that observed in
wild-type islets treated with 250 µM diazoxide and 30 mM KCl in the absence of AOA at each concentration of
glucose (Fig. 6, A-C, closed circles).

View larger version (28K):
[in a new window]
Fig. 6.
KCl-induced insulin release from islets in
the presence of diazoxide. Wild-type islets (closed
circles, n = 4) and mGPDH-deficient islets treated
with 5 mM AOA (closed squares, n = 4) were perifused in the presence of 250 µM diazoxide
and 2.8 mM (A), 10.0 mM
(B), or 16.7 mM (C) glucose
throughout experiments. Depolarizing stimulation by 30 mM
KCl was started at 0 min.

View larger version (26K):
[in a new window]
Fig. 7.
Measurement of ATP content of islets
stimulated by glucose in the presence of diazoxide and KCl.
Wild-type islets (open bars) and mGPDH-deficient islets
treated with 5 mM AOA (filled bars) were
stimulated by 2.8, 10.0, or 16.7 mM glucose in the presence
of 250 µM diazoxide and 30 mM KCl. After
incubation for 1 h, the metabolism was snap-stopped, and the ATP
content of islets was measured with a luciferase assay.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
cells, cardiac myocytes, skeletal muscle, and
brain, and serve to couple cellular metabolic state to electrical
excitability (44). In
cells, the KATP channels are
composed of the inward rectifier potassium channel (Kir) 6.2 (45) and
the sulfonylurea receptor (SUR) 1, a member of the superfamily of ATP
binding cassette proteins (46). Kir6.2 acts as the ATP-sensitive
pore-forming subunit of the KATP channel complex (47, 48),
whereas SUR1 has been identified as the regulatory subunit, which
confers sensitivity to sulfonylureas, channel openers, and
Mg2+ nucleotides (41, 49, 50). The single KATP
channel kinetics (Fig. 4) and its sensitivity to ATP (Fig. 5) on the
excised membrane of mGPDH-deficient
cells were preserved compared
with wild-type
cells, clearly discounting the possibility that the
channel activity itself was impaired secondarily to the absence of
mGPDH. When mGPDH-deficient
cells were treated with AOA to stop the function of the NADH shuttle system, glucose-stimulated generation of
ATP in mitochondria was severely decreased (20). The present study
showed that under these conditions, glucose-stimulated closure of the
KATP channel was severely impaired and subsequent membrane depolarization and generation of action potentials were scarcely observed. These results demonstrated that activation of mitochondrial glucose metabolism through the NADH shuttle system and the resultant increase in cellular ATP content were pivotal to closure of the KATP channel and initiation of the downstream events
leading to insulin secretion.
cells treated with AOA completely preserved the
response to sulfonylurea with respect to the KATP channel current, the plasma membrane potential, and insulin secretion (Fig.
3B and 2D) (20). This was in contrast to the
observation that the effects of sulfonylurea on Ca2+ influx
and insulin secretion were impaired in insulinoma-derived
cells
that were treated for days with ethidium bromide to eradicate mitochondrial DNA, thereby abolishing oxidative phosphorylation (8).
This difference is presumably dependent upon whether glucose-stimulated ATP generation was maintained at ~25% of the normal state (20) or
was almost completely nullified (8). Although the mechanism of
decreased sensitivity of the KATP channel to the drug in
the ATP-depleted state is unclear, it may involve decreased binding of
sulfonylurea to the channel, alteration of the phosphorylation state of
the channel, and defective function of accessory constituent(s) of the channel (8, 51, 52).
cells, a similar
dissociation between [Ca2+]c increase and insulin
secretion was observed (33). A marked dependence of insulin secretion
on energy metabolism has also been postulated as the reason why insulin
secretion was inhibited by cooling, although Ca2+ influx
was only slightly affected by this treatment (53). Moreover, the
omission of ATP from the cytosol resulted in 89% inhibition of
exocytosis elicited by Ca2+ stimulation in permeabilized
insulin-secreting cells (54). Recently, it has also been shown that a
final step of Ca2+-stimulated exocytosis is dependent on
post-priming actions of cytosolic ATP (55). Second, it should also be
noted that the time course of the [Ca2+]c rise to
the second phase plateau in islets was considerably disordered (Fig.
1C, right panel). Disappearance of the initial [Ca2+]c drop suggests that
Ca2+-ATPase of the endoplasmic reticulum may not be able to
sequester cytosolic Ca2+ due to insufficient supply of ATP
(26, 56). Disappearance of the first phase peak of
[Ca2+]c and delay of its elevation to the second
phase level indicated that the closure of KATP channel and
generation of action potentials were severely disturbed, which were
confirmed in single
cells (Fig. 3B and 2C).
Furthermore, we postulate that the elevation of
[Ca2+]c may also be ascribed, at least in part,
to diminished Ca2+ uptake from cytosol by mitochondria (20)
and to diminished Ca2+ extrusion from cytosol by plasma
membrane Ca2+-ATPase. Thus, the
[Ca2+]c rise may not take place at the critical
time and site for the exocytotic processes. Collectively, the reduction
of ATP supply accompanied by the nonphysiological
[Ca2+]c rise appears to be unable to induce
insulin secretion.
cell.
Glucose-induced elevation of [Ca2+]c to the
second phase level did occur in all mGPDH-deficient islets treated with
AOA, although it was considerably delayed. In contrast, glucose-induced
generation of the action potentials, which reflects Ca2+
spikes, was observed in only a small portion of mGPDH-deficient
cells treated with AOA in the same time range. The
cells
constituting an islet are heterogeneous with respect to glucose
metabolism and glucose-induced insulin secretion (57, 58). Although it is not certain how Ca2+ behavior in individual
cells is
manifested in [Ca2+]c change of an islet, it is
possible that a small portion of
cells that preserved electrical
excitability in response to glucose may transmit the signal to adjacent
cells. Thus, the glucose-induced change in
[Ca2+]c that we actually observed in an islet
might be an integration of these localized electrical activities that
took place at various time points after glucose stimulation.
cell metabolism (59, 60), did not
affect glucose-stimulated ATP generation of islets in our study (Fig.
7). Because opening of the KATP channel by diazoxide holds
the plasma membrane potential at a resting level, VDCCs are not
activated in response to glucose. However, application of 30 mM KCl in the presence of diazoxide depolarizes the
membrane, which is followed by Ca2+ influx through VDCCs
and stimulation of insulin secretion. Under these conditions, glucose
is still able to enhance insulin secretion dose-dependently
without significant alteration in [Ca2+]c, which
has been described as the KATP channel-independent Ca2+-dependent pathway of glucose-induced
insulin secretion (31, 32). When glucose-induced insulin secretion was
abolished by the inhibition of the NADH shuttle system, recovery of
insulin secretion through the KATP channel-independent
Ca2+-dependent pathway was observed, and the
extent of recovery was dependent on glucose concentration. However, the
secretion was less than that observed in the presence of the functional
NADH shuttle system (Fig. 6). Under these conditions, the increase in
cellular ATP content of islets in response to glucose was suppressed when the shuttle system was blocked (Fig. 7). In a comprehensive study
to identify regulators of insulin secretion through the KATP channel-independent
Ca2+-dependent pathway, adenine nucleotides
emerged as the best candidate (61). Taken together, ATP generation by
efficient glucose metabolism through the NADH shuttle system probably
functions in the steps distal to [Ca2+]c elevation.
cells. In addition, steps distal to Ca2+ influx into
the cytosol were also affected. These results demonstrate that
mitochondrial metabolism through the NADH shuttle system plays a
central role as a common regulator of both the KATP
channel-dependent pathway leading to
[Ca2+]c elevation and the pathway in which the
elevated [Ca2+]c promotes exocytosis of insulin
from secretory vesicles. Recently, it has been reported that various
steps in glucose-induced insulin secretion are impaired in type 2 diabetes mellitus caused by mutations in the hepatocyte nuclear
factor-1
gene (62, 63). Defects in generation or transport of
glycolysis-derived NADH into mitochondria are implicated in the
impaired insulin secretion (62). Genetic or acquired defects in the
NADH shuttle system may therefore be candidates for the causes of type
2 diabetes mellitus.
| |
ACKNOWLEDGEMENT |
|---|
We thank Hiroshi Chiyonobu for care of the mice.
| |
FOOTNOTES |
|---|
* This work was supported by Grant-in-aid for Creative Basic Research 10NP0201 from the Ministry of Education, Science, Sports, and Culture, Japan (to T. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
** To whom correspondence should be addressed. Tel.: 81-3-3815-5411 (ext. 33111); Fax: 81-3-5689-7209; E-mail: kadowaki-3im@h.u-tokyo.ac.jp.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: KATP, ATP-sensitive potassium; VDCC, voltage-dependent calcium channel; mGPDH, mitochondrial glycerol-3-phosphate dehydrogenase; AOA, aminooxyacetate; [Ca2+]c, cytosolic Ca2+ concentration; Kir, inward rectifier potassium channel; SUR, sulfonylurea receptor.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Vionnet, N., Stoffel, M., Takeda, J., Yasuda, K., Bell, G. I., Zouali, H., Lesage, S., Velho, G., Iris, F., Passa, P., Froguel, P., and Cohen, D. (1992) Nature 356, 721-722[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Sakura, H., Eto, K., Kadowaki, H., Simokawa, K., Ueno, H., Koda, N., Fukushima, Y., Akanuma, Y., Yazaki, Y., and Kadowaki, T. (1992) J. Clin. Endocrinol. Metab. 75, 1571-1573[Abstract] |
| 3. |
Kadowaki, T.,
Kadowaki, H.,
Mori, Y.,
Tobe, K.,
Sakuta, R.,
Suzuki, Y.,
Tanabe, Y.,
Sakura, H.,
Awata, T.,
Goto, Y.,
Hayakawa, T.,
Matuoka, K.,
Kawamori, R.,
Kamada, T.,
Horai, S.,
Nonaka, I.,
Hagura, R.,
Akanuma, Y.,
and Yazaki, Y.
(1994)
N. Engl. J. Med.
330,
962-968 |
| 4. | Grupe, A., Hultgren, B., Ryan, A., Ma, Y. H., Bauer, M., and Stewart, T. A. (1995) Cell 83, 69-78[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Terauchi, Y.,
Sakura, H.,
Yasuda, K.,
Iwamoto, K.,
Takahashi, N.,
Ito, K.,
Kasai, H.,
Suzuki, H.,
Ueda, O.,
Kamada, N.,
Jishage, K.,
Komeda, K.,
Noda, M.,
Kanazawa, Y.,
Taniguchi, S.,
Miwa, I.,
Akanuma, Y.,
Kodama, T.,
Yazaki, Y.,
and Kadowaki, T.
(1995)
J. Biol. Chem.
270,
30253-30256 |
| 6. |
Soejima, A.,
Inoue, K.,
Takai, D.,
Kaneko, M.,
Ishihara, H.,
Oka, Y.,
and Hayashi, J.
(1996)
J. Biol. Chem.
271,
26194-26199 |
| 7. | Kennedy, E. D., Maechler, P., and Wollheim, C. B. (1998) Diabetes 47, 374-380[Abstract] |
| 8. | Tsuruzoe, K., Araki, E., Furukawa, N., Shirotani, T., Matsumoto, K., Kaneko, K., Motoshima, H., Yoshizato, K., Shirakami, A., Kishikawa, H., Miyazaki, J., and Shichiri, M. (1998) Diabetes 47, 621-631[Abstract] |
| 9. |
Hayakawa, T.,
Noda, M.,
Yasuda, K.,
Yorifuji, H.,
Taniguchi, S.,
Miwa, I.,
Sakura, H.,
Terauchi, Y.,
Hayashi, J.,
Sharp, G. W. G.,
Kanazawa, Y.,
Akanuma, Y.,
Yazaki, Y.,
and Kadowaki, T.
(1998)
J. Biol. Chem.
273,
20300-20307 |
| 10. | Matschinsky, F. M. (1996) Diabetes 45, 223-241[Abstract] |
| 11. | Dukes, I. D., and Philipson, L. H. (1996) Diabetes 45, 845-853[Abstract] |
| 12. | Ashcroft, F. M., Proks, P., Smith, P. A., Ammala, C., Bokvist, K., and Rorsman, P. (1994) J. Cell. Biochem. 55 (suppl.), 54-65 |
| 13. | Wollheim, C. B, and Pralong, W. F. (1990) Biochem. Soc. Trans. 18, 111-114[Medline] [Order article via Infotrieve] |
| 14. | Sener, A., Kawazu, S., Hutton, J. C., Boschero, A. C., Devis, G., Somers, G., Herchuelz, A., and Malaisse, W. J. (1978) Biochem. J. 176, 217-232[Medline] [Order article via Infotrieve] |
| 15. |
Zawalich, W. S.,
and Zawalich, K. C.
(1997)
J. Biol. Chem.
272,
3527-3531 |
| 16. |
Dukes, I. D.,
McIntyre, M. S.,
Mertz, R. J.,
Philipson, L. H.,
Roe, M. W.,
Spencer, B.,
and Worley, J. F., III
(1994)
J. Biol. Chem.
269,
10979-10982 |
| 17. |
Mertz, R. J.,
Worley, J. F., III,
Spencer, B.,
Johnson, J. H.,
and Dukes, I. D.
(1996)
J. Biol. Chem.
271,
4838-4845 |
| 18. |
MacDonald, M. J.
(1981)
J. Biol. Chem.
256,
8287-8290 |
| 19. | MacDonald, M. J. (1982) Arch. Biochem. Biophys. 213, 643-649[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Eto, K.,
Tsubamoto, Y.,
Terauchi, Y.,
Sugiyama, T.,
Kishimoto, T.,
Takahashi, N.,
Yamauchi, N.,
Kubota, N.,
Murayama, S.,
Aizawa, T.,
Akanuma, Y.,
Aizawa, S.,
Kasai, H.,
Yazaki, Y.,
and Kadowaki, T.
(1999)
Science
283,
981-985 |
| 21. | Malaisse, W. J., Malaisse-Lagae, F., and Sener, A. (1982) Endocrinology 111, 392-397[Abstract] |
| 22. |
Lebrun, P.,
Malaisse, W. J.,
and Herchuelz, A.
(1983)
Am. J. Physiol.
245,
E38-E46 |
| 23. | Lebrun, P., Malaisse, W. J., and Herchuelz, A. (1984) Horm. Metabol. Res. 16, 322-324[Medline] [Order article via Infotrieve] |
| 24. |
Wolf, B. A.,
Colca, J. R.,
Turk, J.,
Florholmen, J.,
and McDaniel, M. L.
(1988)
Am. J. Physiol.
254,
E121-E136 |
| 25. | Henquin, J. C. (1987) Horm. Res. (Basel) 27, 168-178[Medline] [Order article via Infotrieve] |
| 26. |
Roe, M. W.,
Philipson, L. H.,
Frangakis, C. J.,
Kuznetsov, A.,
Mertz, R. J.,
Lancaster, M. E.,
Spencer, B.,
Worley, J. F., III,
and Dukes, I. D.
(1994)
J. Biol. Chem.
269,
18279-18282 |
| 27. |
Atwater, I.,
Ribalet, B.,
and Rojas, E.
(1978)
J. Physiol.
278,
117-139
|
| 28. | Cook, D. L., and Hales, C. N. (1984) Nature 311, 271-273[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Ashcroft, F. M., Harrison, D. E., and Ashcroft, S. J. (1984) Nature 312, 446-448[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Rorsman, P. (1997) Diabetologia 40, 487-495[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Gembal, M., Gilon, P., and Henquin, J. C. (1992) J. Clin. Invest. 89, 1288-1295 |
| 32. | Sato, Y., Aizawa, T., Komatsu, M., Okada, N., and Yamada, T. (1992) Diabetes 41, 438-443[Abstract] |
| 33. | Rustenbeck, I., Herrmann, C., and Grimmsmann, T. (1997) Diabetes 46, 1305-1311[Abstract] |
| 34. | Sutton, R., Peters, M., and McShane, P. (1986) Transplantation 42, 689-691[Medline] [Order article via Infotrieve] |
| 35. |
Misler, S.,
Falke, L. C.,
Gillis, K.,
and McDaniel, L.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
7119-7123 |
| 36. | Hamill, O. P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F. J. (1981) Pflügers Arch. 391, 85-100[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Suga, S., Kanno, T., Nakano, K., Takeo, T., Dobashi, Y., and Wakui, M. (1997) Diabetes 46, 1755-1760[Abstract] |
| 38. | Levitan, E. S., and Kramer, R. H. (1990) Nature 348, 545-548[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Sala, S., Parsey, R. V., Cohen, A. S., and Matteson, D. R. (1991) J. Membr. Biol. 122, 177-187[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Malaisse, W. J., and Sener, A. (1987) Biochim. Biophys. Acta 927, 190-195[Medline] [Order article via Infotrieve] |
| 41. | Gribble, F., Tucker, S., and Ashcroft, F. M. (1997) EMBO J. 16, 1145-1152[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Gembal, M., Detimary, P., Gilon, P., Gao, Z. Y., and Henquin, J. C. (1993) J. Clin. Invest. 91, 871-880 |
| 43. |
Aizawa, T.,
Sato, Y.,
Ishihara, F.,
Taguchi, N.,
Komatsu, M.,
Suzuki, N.,
Hashizume, K.,
and Yamada, T.
(1994)
Am. J. Physiol.
266,
C622-C627 |
| 44. | Ashcroft, F. M. (1988) Annu. Rev. Neurosci. 11, 97-118[CrossRef][Medline] [Order article via Infotrieve] |
| 45. |
Inagaki, N.,
Gonoi, T.,
Clement, J. P., IV,
Namba, N.,
Inazawa, J.,
Gonzalez, G.,
Aguilar-Bryan, L.,
Seino, S.,
and Bryan, J.
(1995)
Science
270,
1166-1170 |
| 46. |
Aguilar-Bryan, L.,
Nichols, C. G.,
Wechsler, S. W.,
Clement, J. P., IV,
Boyd, A. E., III,
Gonzalez, G.,
Herrera-Sosa, H.,
Nguy, K.,
Bryan, J.,
and Nelson, D. A.
(1995)
Science
268,
423-426 |
| 47. |
Shyng, S.,
Ferrigni, T.,
and Nichols, C.
(1997)
J. Gen. Physiol.
110,
141-153 |
| 48. | Tucker, S., Gribble, F., Zhao, C., Trapp, S., and Ashcroft, F. M. (1997) Nature 387, 179-183[CrossRef][Medline] [Order article via Infotrieve] |
| 49. | Nichols, C. G., Shyng, S. L., Nestorowicz, A., Glaser, B., Clement, J. P., IV, Gonzalez, G., Aguilar-Bryan, L., Permutt, M. A., and Bryan, J. (1996) Science 272, 1785-1787[Abstract] |
| 50. |
Shyng, S.,
Ferrigni, T.,
and Nichols, C.
(1997)
J. Gen. Physiol.
110,
643-654 |
| 51. | Niki, I., and Ashcroft, S. J. H. (1991) Biochim. Biophys. Acta 1133, 95-101[Medline] [Order article via Infotrieve] |
| 52. | Ashcroft, F. M. (1996) Horm. Metab. Res. 28, 456-463[Medline] [Order article via Infotrieve] |
| 53. |
Ohta, M.,
Nelson, D.,
Nelson, J.,
Meglasson, M. D.,
and Erecinska, M.
(1990)
J. Biol. Chem.
265,
17525-17532 |
| 54. | Regazzi, R., Wollheim, C. B., Lang, J., Theler, J. M., Rossetto, O., Montecucco, C., Sadoul, K., Weller, U., Palmer, M., and Thorens, B. (1995) EMBO J. 14, 2723-2730[Medline] [Order article via Infotrieve] |
| 55. |
Takahashi, N.,
Kadowaki, T.,
Yazaki, Y.,
Ellis-Davies, G. C. R.,
Miyashita, Y.,
and Kasai, H.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
760-765 |
| 56. | Hamakawa, N., and Yada, T. (1995) Cell Calcium 17, 21-31[CrossRef][Medline] [Order article via Infotrieve] |
| 57. | Schuit, F. C. (1996) Horm. Res. (Basel) 46, 99-106[Medline] [Order article via Infotrieve] |
| 58. |
de Vargas, L. M.,
Sobolewski, J.,
Siegel, R.,
and Moss, L. G.
(1997)
J. Biol. Chem.
272,
26573-26577 |
| 59. | Trube, G., Rorsman, P., and Ohno-Shosaku, T. (1986) Pflügers Arch. 407, 493-499[CrossRef][Medline] [Order article via Infotrieve] |
| 60. |
Bergsten, P.,
Gylfe, E.,
Wesslen, N.,
and Hellman, B.
(1988)
Am. J. Physiol.
255,
E422-E427 |
| 61. | Sato, Y., and Henquin, J.-C. (1998) Diabetes 47, 1713-1721[Abstract] |
| 62. |
Dukes, I. D.,
Sreenan, S.,
Roe, M. W.,
Levisetti, M.,
Zhou, Y.-P.,
Ostrega, D.,
Bell, G. I.,
Pontoglio, M.,
Yaniv, M.,
Philipson, L.,
and Polonsky, K. S.
(1998)
J. Biol. Chem.
273,
24457-24464 |
| 63. | Wang, H., Maechler, P., Hagenfeldt, K. A., and Wollheim, C. B. (1998) EMBO. J. 17, 6701-6713[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. Polakof, J. M. Miguez, and J. L. Soengas In vitro evidences for glucosensing capacity and mechanisms in hypothalamus, hindbrain, and Brockmann bodies of rainbow trout Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1410 - R1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Martens, Q. Wang, K. Kerckhofs, G. Stange, Z. Ling, and D. Pipeleers Metabolic Activation of Glucose Low-Responsive {beta}-Cells by Glyceraldehyde Correlates with Their Biosynthetic Activation in Lower Glucose Concentration Range But Not at High Glucose Endocrinology, November 1, 2006; 147(11): 5196 - 5204. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Merglen, S. Theander, B. Rubi, G. Chaffard, C. B. Wollheim, and P. Maechler Glucose Sensitivity and Metabolism-Secretion Coupling Studied during Two-Year Continuous Culture in INS-1E Insulinoma Cells Endocrinology, February 1, 2004; 145(2): 667 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamada, M. Komatsu, Y. Sato, K. Yamauchi, T. Aizawa, and I. Kojima Nutrient Modulation of Palmitoylated 24-Kilodalton Protein in Rat Pancreatic Islets Endocrinology, December 1, 2003; 144(12): 5232 - 5241. [Abstract] [Full Text] |